Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Ozempic and other glucagon-like peptide-1 (GLP-1) agonists are a transformative new class of medicines for the treatment of ...

We recently published a list of the 12 Best Long-Term Growth Stocks to Buy Now. In this article, we are going to take a look ...

Novo Nordisk and Eli Lilly have used submissions to the federal government’s budget process to argue reducing obesity will be ...

Sales of Lilly’s incretin medicines, Mounjaro, Trulicity and Zepbound ... Its GLP-1 sales increased 12% at CER. Total Diabetes care rose 17% and Obesity care sales increased 91% at CER.

Released on Friday, February 7, the January jobs report showed resilience in the labor market with higher-than-expected wage ...

Over $600 billion in European goods were imported by the U.S. last year. New tariffs from President Trump will likely hit ...

Mounjaro, manufactured by Lilly, may have emerged as the newest ... on other background drugs being administered as a standard of care. A trial can still be conducted without taking a patient ...

Eli Lilly is just weeks away from launching Mounjaro in the UK ... welcomed by patient organisation Diabetes UK, whose head of care, Douglas Twenefour, said: “Supporting people with type ...

A new study adds to a growing body of research suggesting a potential link between popular GLP-1 medications like Ozempic and vision loss.

Hims & Hers is under scrutiny for promoting compounded weight-loss drugs in a Super Bowl ad without clear FDA approval or ...